Biodesix's (BDSX) "Market Perform" Rating Reaffirmed at William Blair

William Blair reaffirmed their market perform rating on shares of Biodesix (NASDAQ:BDSX - Free Report) in a research report report published on Wednesday, Marketbeat Ratings reports. William Blair also issued estimates for Biodesix's Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.25) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.15) EPS.

Separately, Canaccord Genuity Group reduced their price objective on Biodesix from $3.50 to $2.50 and set a "buy" rating for the company in a research report on Tuesday, April 29th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $2.00.

Biodesix Stock Down 4.4%

Shares of Biodesix stock traded down $0.01 during midday trading on Wednesday, hitting $0.29. The company's stock had a trading volume of 4,477,464 shares, compared to its average volume of 631,758. The firm has a market capitalization of $42.18 million, a P/E ratio of -0.75 and a beta of 1.18. The stock has a 50-day simple moving average of $0.57 and a 200-day simple moving average of $0.98. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix has a 1-year low of $0.17 and a 1-year high of $2.04.

Biodesix (NASDAQ:BDSX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $17.96 million during the quarter, compared to analysts' expectations of $19.50 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. As a group, sell-side analysts expect that Biodesix will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On Biodesix

Institutional investors have recently made changes to their positions in the business. Balyasny Asset Management L.P. bought a new position in Biodesix during the fourth quarter valued at about $29,000. Barclays PLC boosted its holdings in shares of Biodesix by 1,140.5% in the 3rd quarter. Barclays PLC now owns 23,036 shares of the company's stock worth $41,000 after acquiring an additional 21,179 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Biodesix in the 4th quarter worth approximately $52,000. XTX Topco Ltd acquired a new position in shares of Biodesix in the 1st quarter worth approximately $64,000. Finally, MYDA Advisors LLC acquired a new position in shares of Biodesix in the 4th quarter worth approximately $76,000. 20.96% of the stock is currently owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.